GlassScriptPhysician profile
Krystel Babaran
NPI 1558811455
$24,198.64
in general payments reported to CMS, 2019-2025
28 companies · $393 in 2025
The $393 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,228 · 2020: $6,111 · 2021: $3,100 · 2022: $3,420 · 2023: $1,156 · 2024: $791 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $21,000.00 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $460.66 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $434.46 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $396.76 | 2022-2023 | |
| Novo Nordisk INC | $283.92 | 2023-2025 | Wegovy |
| Astellas Pharma US INC | $264.29 | 2022-2025 | Veozah |
| Hologic Sales and Service, LLC | $195.42 | 2021-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Shield Therapeutics INC | $126.89 | 2022-2024 | |
| Organon LLC | $119.07 | 2022-2024 | Nexplanon |
| Abbvie INC. | $111.30 | 2020 | |
| Lupin INC. | $109.68 | 2019 | |
| Gen-Probe, INC. | $106.65 | 2019 | |
| Myriad Women'S Health, INC. | $100.78 | 2023 | Myrisk |
| Biogen, INC. | $71.13 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $62.64 | 2022-2023 | Paragard T 380a |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $55.98 | 2022-2024 | |
| Avion Pharmaceuticals | $52.39 | 2022-2023 | Balcoltra |
| Daiichi Sankyo INC. | $38.68 | 2022 | |
| Agile Therapeutics, INC. | $33.40 | 2022 | |
| Exact Sciences Corporation | $27.48 | 2023 | Cologuard Collection Kit |
| Davol INC. | $24.98 | 2025 | Arista |
| Meditrina | $23.00 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $21.81 | 2023 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2025 | |
| Axonics, INC. | $17.14 | 2024 | Bulkamid |
| Millicent US INC | $15.07 | 2025 | Femlyv |
| Aspira Women'S Health INC | $13.96 | 2024 | Ova1 |
| Acessa Health INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystel Babaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.